Literature DB >> 15648953

CYC-202 Cyclacel.

Timothy Guzi1.   

Abstract

CYC-202, the lead compound from the CYC-200 series of small-molecule cyclin-dependent kinase inhibitors, is under development by Cyclacel for the potential treatment of various cancers and inflammatory diseases, including glomerulonephritis. The compound is currently undergoing phase II clinical trials in non-small-cell lung cancer and breast tumor.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15648953

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  7 in total

1.  Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability.

Authors:  W Jiang; H Huang; L Ding; P Zhu; H Saiyin; G Ji; J Zuo; D Han; Y Pan; D Ding; X Ma; Y Zhang; J Wu; Q Yi; J O Liu; H Huang; Y Dang; L Yu
Journal:  Oncogene       Date:  2014-11-17       Impact factor: 9.867

2.  Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.

Authors:  Fabrizio Galimberti; Sarah L Thompson; Xi Liu; Hua Li; Vincent Memoli; Simon R Green; James DiRenzo; Patricia Greninger; Sreenath V Sharma; Jeff Settleman; Duane A Compton; Ethan Dmitrovsky
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

3.  State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy.

Authors:  Sindura B Ganapathi; Mark Kester; Keith S Elmslie
Journal:  Am J Physiol Cell Physiol       Date:  2009-02-25       Impact factor: 4.249

4.  Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.

Authors:  Binoj C Nair; Sreeram Vallabhaneni; Rajeshwar R Tekmal; Ratna K Vadlamudi
Journal:  Breast Cancer Res       Date:  2011-08-11       Impact factor: 6.466

5.  Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines.

Authors:  Samuel Troadec; Mélina Blairvacq; Nassima Oumata; Hervé Galons; Laurent Meijer; Christian Berthou
Journal:  J Biomed Sci       Date:  2015-07-17       Impact factor: 8.410

6.  Exploration of novel heterofused 1,2,4-triazine derivative in colorectal cancer.

Authors:  Justyna Magdalena Hermanowicz; Anna Szymanowska; Beata Sieklucka; Robert Czarnomysy; Krystyna Pawlak; Anna Bielawska; Krzysztof Bielawski; Joanna Kalafut; Alicja Przybyszewska; Arkadiusz Surazynski; Adolfo Rivero-Muller; Mariusz Mojzych; Dariusz Pawlak
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

7.  Screening and identification of small molecule inhibitors of ErbB2-induced invasion.

Authors:  D M Brix; B Rafn; K Bundgaard Clemmensen; S H Andersen; N Ambartsumian; M Jäättelä; T Kallunki
Journal:  Mol Oncol       Date:  2014-07-12       Impact factor: 6.603
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.